Diabetic Retinopathy Market, By Disease Type (Proliferative Diabetic Retinopathy and Non-proliferative Diabetic Retinopathy), By Treatment Type (Anti-Vascular Endothelial Growth Factor Therapy, Intraocular Steroid Injection, Laser Surgery, Vitrectomy, and Others), By Route of Administration (Intravitreal Injections, Intravitreal Implants, Oral, Topical Eye Drops, Laser Surgery, and Others), By End User (Hospitals, Ophthalmology Clinics, Ambulatory Surgery Centers, Long-Term Care Centers, and Others), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy), By Geography (North America, Latin America, Asia Pacific, Europe, Middle East, and Africa)

Published In : Dec 2024

Code : CMI3313

Pages :140

Formats :

Excel and PDF

Industry : Pharmaceutical

Diabetic Retinopathy Market Size and Trends

The global diabetic retinopathy market is estimated to be valued at USD 9.30 Bn in 2024 and is expected to reach USD 14.31 Bn by 2031, exhibiting a compound annual growth rate (CAGR) of 6.3% from 2024 to 2031.

Diabetic Retinopathy Market Key Factors

To learn more about this report, Request sample copy

The growing prevalence of diabetes worldwide is expected to drive the growth of the diabetic retinopathy market during the forecast period. In November 2021, as per the International Diabetes Federation, approximately 537 million adults aged 20-79 years were living with diabetes in 2021 worldwide, and by 2030, this number is projected to rise to 643 million. Diabetic retinopathy, which is a common complication of diabetes, can potentially lead to blindness if not detected and treated promptly. With rising diabetes population, the prevalence of diabetic retinopathy is also expected to increase substantially in the coming years.

Diabetic Retinopathy Market Regional Insights

To learn more about this report, Request sample copy

Top Strategies Followed by Global Diabetic Retinopathy Market Players

Established Players: Leading companies prioritize extensive R&D to innovate high-performance products. For instance, in April 2017, Genentech, a subsidiary of Roche, received the U.S. Food and Drug Administration approval for Lucentis (ranibizumab injection) 0.3 mg, a treatment for diabetic retinopathy, highlighting its commitment to advancing therapeutic options.
Mid-Level Players: Several mid-sized companies focus on delivering quality, budget-friendly products. Partnerships enhance technology and market presence. In May 2024, Optomed Oyj and AEYE Health received U.S. Food and Drug Administration clearance for a portable device combining Optomed's fundus camera with AEYE's AI technology, enabling autonomous diabetic retinopathy screening.
Small-Scale Players are targeting specific markets with unique products. In May 2024, Ocular Therapeutix developed sustained-release therapies like Axpaxli (OTX-TKI) for diabetic retinopathy, focusing on innovative drug delivery To maintain a competitive edge, AEYE Health is leveraging AI-powered diagnostic systems for the swift detection of diabetic retinopathy, with approval from the U.S. FDA in April 2024.

Emerging Startups in the Global Diabetic Retinopathy Market

Innovative Technologies: AEYE Health developed an AI-based diagnostic system, AEYE-DS, enabling rapid diabetic retinopathy detection. In April 2024, the U.S. Food and Drug Administration approved this system, facilitating widespread autonomous screening. These technologies enhance early detection and treatment, potentially reducing the global burden of diabetic retinopathy. AI-driven diagnostics improve accuracy and accessibility, leading to better patient outcomes.

Sustainable Solutions: RetroSense Therapeutics is researching bio-degradable, 3D printed implants as an alternative to anti-VEGF injections for wet age-related macular degeneration diabetic retinopathy. Cavitar is developing a natural extract from maple tree sap that may reduce retinopathy progression in a eco-friendly manner. Partnerships with established companies and research institutions drive technological innovation and expand market reach, enhancing the overall quality of diabetic retinopathy care.